These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17298106)

  • 21. The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury.
    Paytash CA
    Stanford Law Rev; 1999 May; 51(5):1343-71. PubMed ID: 10558426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical inserts: legal consequences.
    Hirsh HL
    Hosp Med Staff; 1979 Jul; 8(7):2-6. PubMed ID: 10242674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.
    Kopp SW; Bang HK
    Health Mark Q; 2000; 17(3):39-56. PubMed ID: 11010219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Educating patients about their medications: the potential and limitations of written drug information.
    Shrank WH; Avorn J
    Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription drug products; patient labeling requirements: proposed rule.
    Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
    [No Abstract]   [Full Text] [Related]  

  • 26. The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling.
    Dinatale M; Roca C; Sahin L; Johnson T; Mulugeta LY; Fletcher EP; Yao L
    J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S18-S25. PubMed ID: 33274508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription of hazardous drugs during pregnancy.
    Malm H; Martikainen J; Klaukka T; Neuvonen PJ
    Drug Saf; 2004; 27(12):899-908. PubMed ID: 15366977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Requirements for FDA-approved patient information spelled out in final rule.
    Am J Health Syst Pharm; 1999 Jan; 56(2):107-8. PubMed ID: 10030523
    [No Abstract]   [Full Text] [Related]  

  • 29. Deficiencies of product labeling directions for the preparation of radiopharmaceuticals.
    Hung JC; Ponto JA; Gadient KR; Frie JA; Aksamit CM; Enquist CL; Carrels KE
    J Am Pharm Assoc (2003); 2004; 44(1):30-5. PubMed ID: 14965150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug safety labeling for doctors.
    Hecht A
    FDA Consum; 1979 Oct; 13(8):12-3. PubMed ID: 10309108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Categorizing the safety of medications during pregnancy and lactation.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Apr; 47(4):17-20. PubMed ID: 19437927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
    Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
    Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Patient-oriented package inserts for drugs. Historical overview and current status].
    Van Haecht CH; Vander Stichele R; Bogaert M
    Arch Belg; 1989; 47(5-6):230-55. PubMed ID: 2700065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
    Willy ME; Li Z
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
    Roberts R; Rodriguez W; Murphy D; Crescenzi T
    JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory study of drug abuse and dependence information in package inserts.
    Phipps LB; Balster RL; Slattum PW; Kirkwood CK
    J Addict Dis; 2007; 26(2):25-34. PubMed ID: 17594995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rx with a dose of info.
    Miller RW
    FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug package inserts and the adequacy of patient's drug information].
    da Silva T; Dal-Pizzol F; Bello CM; Mengue SS; Schenkel EP
    Rev Saude Publica; 2000 Apr; 34(2):184-9. PubMed ID: 10881155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk classification systems for drug use during pregnancy: are they a reliable source of information?
    Addis A; Sharabi S; Bonati M
    Drug Saf; 2000 Sep; 23(3):245-53. PubMed ID: 11005706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication use in pregnancy and the pregnancy and lactation labeling rule.
    Sahin L; Nallani SC; Tassinari MS
    Clin Pharmacol Ther; 2016 Jul; 100(1):23-5. PubMed ID: 27082701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.